---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-028368"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2026-07-14T11:30:53+00:00"
generated_at: "2026-07-14T11:35:12.840605+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics reports FY2026 Q4 pro forma sales $86.6M (+8% YoY); Med Tech growth 16.7%

## Summary
- Q4 FY2026 pro forma net sales $86.6M (+8.0% YoY); Med Tech $41.8M (+16.7%), Med Device $44.8M (+1.1%).
- Full year pro forma net sales $320.2M (+9.4%); GAAP net loss $36.7M ($0.88 loss per share); adjusted EBITDA $13.2M.
- FY2027 guidance: net sales $336M-$341M, Med Tech growth 12-15%, adjusted EBITDA $13M-$16M, adjusted EPS ($0.29)-($0.24).
- Clinical milestones: FDA IDE approvals for APEX-Return, PAVE, RELIEF studies; Palmetto GBA LCD for NanoKnife IRE in prostate/liver cancer.
- Ended FY2026 with $53.9M cash, debt-free; tariff headwinds $4.8M in FY2026, expected similar in FY2027.

## SEC filing metadata
- accession: 0001140361-26-028368
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2026-07-14T11:30:53+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036126028368/0001140361-26-028368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036126028368/ef20077916_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-028368
- JSON: https://secwatch.observer/filing/0001140361-26-028368.json
- Plain text: https://secwatch.observer/filing/0001140361-26-028368.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.